Education
About Us
Working with TipRanks
Follow Us
ImmuPharma PLC (GB:IMM)
LSE:IMM
Total Valuation
ImmuPharma has a market cap or net worth of £13.34M. The enterprise value is ―.
Market Cap£13.34M
Enterprise Value―
Share Statistics
ImmuPharma has 499,723,940 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding499,723,940
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
ImmuPharma’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee0.00
Profits Per Employee-584.36K
Employee Count5
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of ImmuPharma is ―. ImmuPharma’s PEG ratio is ―.
PE Ratio―
PS Ratio0.00
PB Ratio―
Price to Fair Value―
Price to FCF―
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, ImmuPharma had revenue of 0.00 and earned -2.92M in profits. Earnings per share was -0.01.
Revenue0.00
Gross Profit-37.61K
Operating Income-3.06M
Pretax Income-3.42M
Net Income-2.92M
EBITDA-3.03M
Earnings Per Share (EPS)-0.01
Cash Flow
In the last 12 months, operating cash flow was -1.59M and capital expenditures 2.00, giving a free cash flow of -1.59M billion.
Operating Cash Flow-1.59M
Free Cash Flow-1.59M
Free Cash Flow per Share>-0.01
Dividends & Yields
ImmuPharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.80
52-Week Price Change6.80%
50-Day Moving Average2.84
200-Day Moving Average2.49
Relative Strength Index (RSI)43.34
Average Volume (3m)2.74M
Important Dates
ImmuPharma upcoming earnings date is Sep 25, 2025, TBA Not Confirmed.
Last Earnings DateMay 19, 2025
Next Earnings DateSep 25, 2025
Ex-Dividend Date―
Financial Position
ImmuPharma as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, ImmuPharma has paid -497.10K in taxes.
Income Tax-497.10K
Effective Tax Rate―
Enterprise Valuation
ImmuPharma EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
ImmuPharma has £1.08M in cash and marketable securities with £0.00 in debt, giving a net cash position of -£1.08M billion.
Cash & Marketable Securities£1.08M
Total Debt£0.00
Net Cash-£1.08M
Net Cash Per Share>-£0.01
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for ImmuPharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―